Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
496.83
+16.70 (3.48%)
At close: Feb 27, 2026, 4:00 PM EST
496.10
-0.73 (-0.15%)
After-hours: Feb 27, 2026, 7:58 PM EST
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 526.79, with a low estimate of 414 and a high estimate of 607. The average target predicts an increase of 6.03% from the current stock price of 496.83.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock from 27 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 8 | 8 |
| Buy | 8 | 8 | 8 | 9 | 12 | 12 |
| Hold | 9 | 10 | 10 | 8 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 25 | 26 | 26 | 24 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $411 → $441 | Hold | Maintains | $411 → $441 | -11.24% | Feb 17, 2026 |
| Barclays | Barclays | Buy Maintains $606 → $607 | Buy | Maintains | $606 → $607 | +22.17% | Feb 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $518 → $591 | Strong Buy | Maintains | $518 → $591 | +18.95% | Feb 17, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $495 → $558 | Hold | Maintains | $495 → $558 | +12.31% | Feb 13, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $546 → $541 | Buy | Maintains | $546 → $541 | +8.89% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
13.33B
from 12.00B
Increased by 11.10%
Revenue Next Year
14.70B
from 13.33B
Increased by 10.23%
EPS This Year
20.39
from 15.32
Increased by 33.08%
EPS Next Year
22.88
from 20.39
Increased by 12.24%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 14.2B | 17.2B | |||
| Avg | 13.3B | 14.7B | |||
| Low | 12.1B | 12.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.2% | 29.0% | |||
| Avg | 11.1% | 10.2% | |||
| Low | 0.5% | -4.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 23.43 | 29.61 | |||
| Avg | 20.39 | 22.88 | |||
| Low | 17.79 | 18.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 52.9% | 45.2% | |||
| Avg | 33.1% | 12.2% | |||
| Low | 16.1% | -10.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.